The review lays out five interconnected processes that govern the fate of mRNA-lipid nanoparticles in the body: route-dependent transport and initial tissue distribution, interactions with blood proteins that form the so-called protein corona, receptor-mediated cellular uptake and organ tropism, endosomal escape and intracellular trafficking, and finally metabolic degradation and immune-mediated clearance. These pathways act sequentially, meaning that a change at any stage ripples through the entire pharmacokinetic profile. Crucially, the authors emphasize that the localization of LNP-associated lipids, intact mRNA, and encoded protein follows distinct spatial and temporal patterns, so detecting one component cannot be assumed to demonstrate the presence or activity of another. Apparent contradictions between studies using radiolabeling, molecular quantification, imaging, or protein-based readouts often reflect differences in the biological endpoint measured rather than genuinely conflicting results.

Administration route emerges as one of the most powerful determinants of biodistribution. Intramuscular and subcutaneous injection favor retention at the injection site followed by drainage to regional lymph nodes, with peak tissue concentrations typically occurring within two to eight hours; subcutaneous delivery produces similar patterns but with slower kinetics and prolonged persistence. Intravenous administration bypasses local lymphatics entirely, producing immediate systemic exposure with predominant accumulation in the liver. Respiratory delivery via intranasal, intratracheal, or nebulized routes deposits nanoparticles throughout the airway epithelium according to aerodynamic diameter, bypassing first-pass hepatic clearance and enabling mucosal immunity characterized by secretory IgA and tissue-resident memory T cells. The review notes, however, that intranasal delivery is not straightforward, as animal studies suggest some formulations may be reactogenic.

Perhaps the most striking examples of route-driven tropism come from less conventional approaches. Intraperitoneal administration of ionizable LNPs has been shown to deliver mRNA to pancreatic beta cells through an indirect mechanism in which peritoneal macrophages internalize the particles before transferring functional mRNA to pancreatic islets, largely avoiding the hepatic dominance seen after intravenous injection. More recently, researchers identified a pancreas-selective delivery mechanism based on organ capsule filtration, in which arginine-histidine-modified LNPs undergo protein-induced size enlargement after systemic administration, allowing preferential accumulation within the pancreatic capsule. This platform achieved efficient delivery of Cas9 mRNA and therapeutic cytokine mRNAs in rodents and non-human primates, demonstrating that particle size, protein association, organ anatomy, and administration route act synergistically to determine organ selectivity rather than lipid chemistry alone.

Intrathecal injection, which introduces nanoparticles directly into cerebrospinal fluid, bypasses the blood-brain barrier and enables widespread distribution across the brain and spinal cord. Biodegradable brain-targeting LNPs have achieved reporter expression in the cortex, hippocampus, and cerebellum, transfecting both neurons and astrocytes, while related work delivered CRISPR genome-editing components throughout the central nervous system with limited peripheral exposure. Notably, formulation chemistry remained a critical determinant even within this route, with ionizable lipid structure influencing both cellular uptake and regional distribution. Subretinal injection likewise places formulations directly adjacent to the retinal pigment epithelium and photoreceptors, enabling robust local transfection for inherited retinal disorders while minimizing systemic exposure. Even the choice of limb for sequential vaccine doses matters: murine studies showed enhanced early germinal center B-cell responses and higher-affinity antibodies following ipsilateral boosting, although these differences diminished over time, with comparable long-term protection regardless of injection side.

Once nanoparticles reach biological fluids, they rapidly adsorb plasma proteins to form a protein corona that replaces the synthetic surface as the interface recognized by cells. Apolipoprotein E is the best-characterized component, promoting uptake through low-density lipoprotein receptor family members and explaining the intrinsic hepatic tropism of many formulations. But quantitative proteomics reveals a far more complex picture: the corona is a dynamic mixture of high-density lipoproteins, albumin, vitronectin, complement proteins, immunoglobulins, fibrinogen, prothrombin, C-reactive protein, and alpha-2-macroglobulin, whose composition depends on lipid chemistry, administration route, and host physiology. HDL has been associated with enhanced uptake and transfection, albumin prolongs circulation by improving colloidal stability, and complement proteins and immunoglobulins accelerate clearance by the mononuclear phagocyte system, potentially contributing to complement activation-related pseudoallergy and anti-PEG immune responses during repeated dosing. Formulations with nearly identical physical properties can therefore exhibit markedly different tissue tropism because organ selectivity is determined by the integrated corona composition rather than any single protein.

Even successful cellular uptake does not guarantee productive delivery. The review identifies endosomal escape as the principal intracellular bottleneck, with only a small fraction of internalized nanoparticles releasing intact mRNA into the cytoplasm before lysosomal degradation. Ionizable lipids facilitate escape by becoming protonated within acidifying endosomes, destabilizing the endosomal membrane, but recent in vivo LysoTag and lysosomal barcoding studies have provided the first quantitative measurements of escape kinetics, showing that relatively small improvements in escape efficiency produce disproportionately large increases in protein expression. This finding shifts the focus of formulation optimization from maximizing tissue uptake toward improving intracellular trafficking and cytosolic release. Once released, mRNA undergoes ribosomal translation before rapid degradation by endogenous ribonucleases, while the encoded protein frequently persists considerably longer, creating a temporal dissociation between nanoparticle localization, mRNA persistence, and biological activity that explains why different analytical methods yield different pharmacokinetic profiles for the same formulation.

The human evidence, though less comprehensive, broadly supports the preclinical picture. After intramuscular vaccination, vaccine-derived mRNA and encoded spike protein can be transiently detected in plasma within the first few hours, consistent with systemic dispersion of a small fraction of the dose. Lymph node biopsies confirm local expression in germinal-center B cells and dendritic cells, correlating with strong antibody and T-cell responses. One study using RT-qPCR detected vaccine mRNA in lymph nodes, liver, spleen, and myocardium from recently vaccinated individuals, with persistence up to 30 days in some axillary lymph nodes, but the authors of that work concluded that observed cardiac changes likely reflected pre-existing conditions rather than direct vaccine effects. Quantitative imaging in non-human primates has found no evidence of significant mRNA or lipid presence in brain tissue, and examination of gonadal tissues reveals only trace, fragmented RNA species without functional translation. The placenta, meanwhile, appears to be selectively targetable: optimized ionizable LNPs efficiently transfected placental trophoblasts with minimal fetal transfer in pregnant mice and ex vivo human placental perfusion systems, opening possibilities for treating pre-eclampsia and fetal growth restriction.

Clearance kinetics are now better characterized as well. In most models, mRNA persists for less than 48 hours before enzymatic breakdown, while lipid components are metabolized more slowly through hepatic and biliary routes; PEG-lipids and cholesterol derivatives may remain for several days, particularly within macrophages, but are gradually cleared without significant histopathological changes. Mass spectrometry studies of a biodegradable ionizable lipid showed complete hepatobiliary and renal clearance by 168 hours despite rapid systemic distribution of lipid-derived radioactivity. Repeated exposure to PEG-containing formulations may induce anti-PEG antibodies and complement activation, leading to accelerated blood clearance and altered biodistribution after subsequent administrations, a phenomenon driving the development of PEG-free alternatives. Cross-species comparisons reveal that rodents tend to overestimate hepatic accumulation relative to humans, while non-human primates better replicate human plasma kinetics but differ in immune activation thresholds, prompting growing interest in organ-on-chip systems, organoids, and humanized models to improve translational accuracy.

Looking forward, the review argues that rational, data-driven engineering is replacing empirical formulation. Selective organ targeting (SORT) lipids redirect expression from liver to spleen, lung, or bone marrow in a charge-dependent manner; biodegradable ionizable lipids with ester or ketal linkages reduce long-term retention while maintaining delivery efficiency; and barcode-based screening now enables high-throughput evaluation of hundreds of formulations within a single animal. Artificial intelligence and machine learning are accelerating lipid design, with graph neural networks predicting blood-brain barrier permeability and generative models proposing novel ionizable structures, though the authors caution that most models are trained on small, heterogeneous datasets and require rigorous external validation. Physiologically based pharmacokinetic and quantitative systems pharmacology models are increasingly integrating these diverse data streams to predict tissue exposure and protein expression across species. The overarching message is clear: biodistribution cannot be defined by a single analytical signal, and progress toward clinically predictable mRNA therapeutics will depend on determining not only where each formulation distributes, but which cells receive intact cargo, whether functional expression occurs, and how long its effects persist.

Subject of Research: Biodistribution and pharmacokinetics of mRNA lipid nanoparticle delivery systems

Article Title: Mechanisms and determinants of mRNA Lipid Nanoparticle biodistribution: From pharmacokinetics to clinical translation

Article References: Alhareth, Z., & López‐Camacho, C. (2026). Mechanisms and determinants of mRNA Lipid Nanoparticle biodistribution: From pharmacokinetics to clinical translation. Bioengineering & Translational Medicine, Article e70183. https://doi.org/10.1002/btm2.70183

Image Credits: AI Generated

DOI: 10.1002/btm2.70183

Keywords: mRNA therapeutics, lipid nanoparticles, biodistribution, protein corona, endosomal escape, pharmacokinetics, drug delivery, SORT lipids, intrathecal delivery, placental transfer, PBPK modeling, clinical translation

The standard manufacturing workflow for approved CAR T cell therapies involves isolating a patient’s own T cells, introducing a CAR-encoding gene, expanding the cells, and reinfusing them. Viral vectors achieve stable CAR expression but carry well-known liabilities: the risk of insertional mutagenesis, potential immunogenicity, limited cargo capacity, labor-intensive production, and costs that restrict broader clinical access. Electroporation, the clinical standard for mRNA transfection of T cells, requires specialized equipment and compromises membrane integrity, reducing viability and altering cellular physiology in ways that demand additional safety evaluation.

Messenger RNA offers an attractive middle path. Because it does not integrate into the genome and drives only transient CAR expression, it confers a self-limiting safety profile, confining receptor expression to a defined window of days. mRNA-based CAR T cells have already shown efficacy against acute lymphoblastic leukemia, melanoma, and Hodgkin lymphoma comparable to virally transduced cells. The challenge has always been delivery: naked mRNA is inherently unstable and cannot cross the cell membrane on its own, so a carrier is essential.

The research team, led by investigators at Shanghai University and the Shanghai Cell Therapy Group, synthesized a library of eight novel ionizable lipids as structural analogs of previously reported candidates effective in immune cell transfection. Each lipid was formulated into a nanoparticle by microfluidic mixing with a fixed excipient composition: cholesterol for membrane integrity and stability, the phospholipid DOPE to facilitate endosomal escape, and the PEG-lipid DMG-PEG2000 to confer colloidal stability and reduce nonspecific uptake. Holding the excipient ratios constant allowed the researchers to isolate the effect of the ionizable lipid head group during screening.

Dynamic light scattering and RiboGreen assays confirmed that all eight formulations were monodisperse, with Z-average diameters between 79.6 and 97.2 nanometers, polydispersity indices between 0.107 and 0.180, and mRNA encapsulation efficiencies above 95 percent. When screened in the murine dendritic cell line DC2.4 and in activated human peripheral blood mononuclear cells using eGFP mRNA, four of the eight candidates transfected more than 90 percent of DC2.4 cells, and lipid 6 emerged as the clear leader, delivering the highest eGFP positivity rates and mean fluorescence intensity and surpassing the clinically validated benchmark lipid ALC-0315.

In vivo validation using firefly luciferase mRNA in mice showed that lipid 6 elicited significantly higher luciferase expression than the benchmark lipids SM-102 and ALC-0315 at the six-hour time point for both intravenous and intramuscular routes. Intravenous injection produced the strongest systemic signal, whereas intramuscular administration yielded a more prolonged, localized signal that remained detectable at the injection site 72 hours after dosing. The researchers then systematically optimized the formulation using a design-of-experiments approach, screening 26 formulations across two rounds by varying the stoichiometry of the four LNP components. Both the ionizable lipid and DMG-PEG2000 concentrations exerted the strongest influence on transfection outcomes, and the team selected a formulation with reduced PEG-lipid content to minimize potential immunogenicity.

Titrating the nitrogen-to-phosphate ratio revealed that eGFP positivity increased with the ratio and plateaued at a value of 5, while mean fluorescence intensity peaked at a ratio of 10 before declining. Supplementing the transfection with recombinant APOE4 boosted efficiency, which plateaued at 1 microgram per milliliter, and an mRNA dose of 150 nanograms per 500,000 cells proved saturating. Under the finalized protocol, more than 90 percent of primary human T cells, natural killer cells, and dendritic cells expressed eGFP, and tumor-infiltrating lymphocytes isolated from hepatocellular carcinoma tissues exceeded 97 percent positivity. Both activated and unactivated T cells were transfected efficiently, at greater than 95 percent and greater than 80 percent positivity respectively. Storage testing showed the nanoparticles remained remarkably stable at 4 degrees Celsius, maintaining high cell viability and roughly 100 percent eGFP expression for up to 110 days, but performance collapsed within two weeks at 25 or 37 degrees Celsius.

The pivotal demonstration came when the team encapsulated mRNA encoding a MUC1-targeting CAR in lipid 6. Roughly 90 percent of transfected T cells expressed the CAR protein 24 hours after transfection, with CD4-positive and CD8-positive subset ratios unchanged and no significant upregulation of the exhaustion markers PD-1, LAG-3, or TIM-3. In real-time cytotoxicity assays, the engineered cells showed significantly enhanced killing of MUC1-expressing MDA-MB-468 breast cancer cells and SKOV3 ovarian cancer cells at every effector-to-target ratio tested, accompanied by markedly increased secretion of the Th1-type cytokines IL-2, TNF-alpha, and IFN-gamma. Longitudinal tracking showed CAR expression peaked at 24 hours and declined to below 5 percent by day 4, yet the cells retained significantly higher tumor-killing capacity than controls at each of the first three days after transfection, all while maintaining normal proliferation and viability.

Transcriptomic sequencing of lipid 6-transfected T cells reinforced the mechanistic picture. Gene Ontology enrichment pointed to upregulation of gene sets involved in transmembrane transport, membrane dynamics, cell junction organization, and intracellular trafficking, consistent with enhanced endosomal escape and cytosolic mRNA release. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed robust activation of cytokine-cytokine receptor interactions, T cell receptor signaling, chemokine signaling, and Th1/Th2 differentiation pathways, indicating that the delivery process triggered physiological T cell activation without exhaustion or aberrant inflammatory signaling. Notably, unlike liver-tropic lipid nanoparticles that depend on APOE-mediated uptake, lipid 6 appears to operate in immune cells through alternative endocytic pathways, though the precise intracellular trafficking and endosomal escape mechanisms remain to be fully elucidated.

The authors are candid about the study’s limitations. All cellular assessments were confined to in vitro experiments, so long-term antitumor efficacy, biodistribution, and biosafety in tumor-bearing animal models remain unverified. Only a MUC1-targeted CAR was examined, leaving the platform’s generality across other tumor antigens untested, and scalable GMP-level production processes have not yet been established. The transient nature of mRNA expression, while a safety advantage, may also limit therapeutic persistence in solid tumor microenvironments. Even so, the work establishes a rationally designed, nonviral platform that overcomes the insertional mutagenesis risks, cellular damage, and prohibitive costs associated with viral vectors and electroporation, and it points toward a future in which CAR T cells and other engineered immune cell therapies can be manufactured more safely, more scalably, and more affordably.

Subject of Research: Lipid nanoparticle-mediated mRNA delivery for nonviral CAR T cell engineering

Article Title: Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity

Article References: Gao, H., Fang, Y., Tian, Z., Guo, C., Wang, P., Liu, T., Sun, Y., Zhang, P., & Qian, Q. (2026). Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity. iScience, 29(10), Article 117390. https://doi.org/10.1016/j.isci.2026.117390

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117390

Keywords: CAR T cells, lipid nanoparticles, mRNA delivery, ionizable lipids, immunotherapy, nonviral gene delivery, MUC1, T cells, endosomal escape, cancer therapy, transient expression, ex vivo engineering

The stakes of this delivery problem are easy to appreciate when one considers the enzymes involved. Adenine base editors, first described by Gaudelli and colleagues in 2017, are programmable molecular machines that convert A•T base pairs to G•C in genomic DNA without making a double-strand break. Their precision and safety profile have made them attractive candidates for treating genetic disease, but they are encoded by messenger RNAs that are substantially longer than those used in early LNP applications. Cas9 messenger RNA itself already stretches the formulation envelope, and base editors push it further. When a delivery vehicle is asked to carry a transcript several kilobases long, the physics and chemistry of how lipids and RNA organize into a nanoparticle change in ways that conventional screening pipelines, which typically rely on short reporter RNAs, never register.

The clinical context sharpens the urgency. The pivotal trial by Frangoul and colleagues that produced the first approved CRISPR therapy for sickle cell disease and beta-thalassemia relied on ex vivo editing of harvested cells, sidestepping the delivery challenge entirely. In vivo editing is a different proposition. Gillmore and colleagues showed in a first-in-human trial that lipid nanoparticle-delivered CRISPR-Cas9 can edit the liver to treat transthyretin amyloidosis, and Rothgangl and colleagues demonstrated in macaques that LNP-based adenine base editing of PCSK9 can durably reduce LDL cholesterol. These landmark results prove that LNP-mediated in vivo editing works, but they also reveal how much of the therapeutic potential remains locked behind the efficiency ceiling of current formulations. Every incremental improvement in delivery translates into lower doses, reduced off-target exposure, and access to tissues beyond the liver.

Dong and colleagues approached the problem by asking a deceptively simple question: what happens to a lipid nanoparticle when the RNA inside it is the size of a gene editor’s transcript? The answer, revealed through structural characterization, is that the cargo is not a passive passenger. Large messenger RNAs alter how ionizable lipids and nucleic acids pack together, producing nanoparticles whose internal organization differs from those formed with short RNAs. Because the structure of an LNP governs its behavior in the body, particularly its ability to escape the endosome, the membrane-bound compartment that engulfs incoming particles after cellular uptake, a structurally compromised particle is a poorly functional one. Endosomal escape is widely regarded as the critical bottleneck in RNA delivery; only a small fraction of nanoparticles that enter a cell ever release their payload into the cytoplasm, where translation can begin.

Armed with this structural insight, the team built their screening strategy around the principle that the assay should match the application. Instead of evaluating candidate ionizable lipids with compact reporter RNAs, they screened formulations using a gene-editor-sized RNA, ensuring that the structural and functional properties being measured were those that would actually matter in a therapeutic context. This cargo-matched screening identified a lead ionizable lipid, designated LC-1, that had presumably been overlooked or underappreciated in conventional screens because its advantages only manifest when the RNA cargo is large.

The mechanistic payoff of LC-1 lies in endosomal escape. Structural analysis showed that LC-1-containing nanoparticles form an internal arrangement that enhances the release of large RNA payloads from endosomes, directly attacking the step that limits cytoplasmic delivery. This is a notable example of structure-guided formulation design: rather than treating the ionizable lipid as a tunable parameter optimized through iterative empirical variation, the study connects a specific lipid-dependent structural feature to a specific biological bottleneck, and then exploits that connection to select a superior candidate. The finding suggests that the field’s extensive libraries of ionizable lipids may contain many molecules whose true strengths and weaknesses are invisible unless they are tested with realistic cargo.

The functional consequences were validated across three tissues in mice. LC-1-based nanoparticles enabled efficient genome editing in the liver, the traditional stronghold of LNP delivery, but also in the lung and the brain, tissues that have historically been far more difficult targets for intravenously or systemically administered lipid nanoparticles. Achieving robust editing in the lung and brain hints at therapeutic applications that extend well beyond hepatology, from respiratory genetic diseases to central nervous system disorders, although the authors’ mouse data represent an early step on a long translational road. Tissue tropism in LNP delivery is governed by a complex interplay of particle properties, route of administration, and interactions with serum proteins, and the study’s title, which references both large RNA cargo optimization and tissue targeting, indicates that the formulation work was designed with this broader targeting problem in mind.

For the field, the most consequential message may be methodological. LNP development has historically been accelerated by combinatorial chemistry and high-throughput screening, approaches that generated the lipid libraries behind today’s clinical products. But if the performance of an ionizable lipid depends on the size of the RNA it carries, then screening campaigns built on small reporter RNAs may systematically misrank candidates for the applications that matter most, namely the delivery of long editor transcripts. The Dong study effectively establishes cargo-matched screening as a design principle: the RNA used in the assay should approximate the size and presumably the structural behavior of the therapeutic payload. This recalibration could redirect attention to existing lipids that were dismissed in earlier screens and could change how new libraries are evaluated.

The work also deepens a conceptual shift that has been gathering momentum in drug delivery research. Nanoparticles are increasingly understood not as inert shells but as self-assembled systems whose components, including the cargo itself, co-determine the final architecture and thus the biological performance. A several-kilobase messenger RNA is not merely a payload to be protected; it is a structural element of the particle, influencing lipid packing, internal morphology, and ultimately endosomal escape. Recognizing the cargo as a design variable opens a second axis of optimization alongside lipid chemistry: formulators can now think about matching vehicle to payload the way structural biologists think about matching ligand to binding pocket.

Cautious optimism is warranted. The reported results are preclinical, generated in mice, and the translation of LNP performance from rodents to humans has historically involved surprises in biodistribution, tolerability, and potency. Nevertheless, the study arrives at a moment when in vivo gene editing is transitioning from proof-of-concept to therapeutic platform, with liver-directed CRISPR therapies already tested in patients and base editors advancing through development for indications ranging from hypercholesterolemia to genetic blindness. Delivery efficiency is the variable that determines dose, safety margin, and tissue reach for all of these programs. By showing that cargo size matters, that structure explains why, and that a cargo-matched screen can find lipids like LC-1 that unlock efficient editing in liver, lung, and brain, the researchers have supplied the field with both a practical tool and a conceptual correction. The next generation of gene-editing medicines will likely be formulated not around generic nanoparticles, but around vehicles designed for the specific, oversized molecular machines they must deliver.

Subject of Research: Lipid nanoparticle design for delivery of large gene-editor mRNA cargo

Article Title: Cargo size matters when designing lipid nanoparticles for delivery of large gene editors

Article References: Cargo size matters when designing lipid nanoparticles for delivery of large gene editors. (2026). Nature Biotechnology. https://doi.org/10.1038/s41587-026-03297-9 (Author names are not included in the publisher’s citation export.)

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03297-9

Keywords: lipid nanoparticles, gene editing, base editors, ionizable lipids, endosomal escape, mRNA delivery, LC-1, in vivo genome editing, drug delivery, nucleic acid therapeutics, tissue targeting, CRISPR

The problem the researchers set out to solve is rooted in the physics of how lipid nanoparticles form. These particles assemble spontaneously when ionizable lipids, helper lipids, cholesterol, polyethylene glycol lipids and RNA are mixed in carefully controlled conditions. The ionizable lipid is the star of the show: it is positively charged at acidic pH, which allows it to bind and encapsulate negatively charged RNA, but neutral in the bloodstream, which limits toxicity. Decades of optimization have produced lipids such as ALC-0315, used in the Pfizer-BioNTech vaccine, and LP-01, a benchmark for in vivo editing studies. But those lipids were largely selected using short reporter RNAs, and their efficiency drops measurably when the transcript grows to the size of a full-length Cas9 mRNA, which can exceed four kilobases.

That size penalty matters enormously for genome editing. Unlike small interfering RNAs or compact vaccine transcripts, the mRNAs that encode CRISPR nucleases and base editors are among the largest RNAs anyone would want to deliver. Adenine base editor mRNA, for example, stretches to roughly 5.7 kilobases, and it must be co-delivered with a guide RNA and then translated into a functional protein inside the target cell. Viral vectors such as adeno-associated virus struggle to fit such cargo into a single genome, and preexisting immunity to Cas9 proteins and to viral capsids raises additional safety concerns. Nonviral delivery by lipid nanoparticles avoids those constraints, but only if the particle can actually get its bulky payload into the cytoplasm.

To find lipids suited to large transcripts, the Toronto group, led by Bowen Li with co-first authors Songtao Dong, Fanglin Gong and Tyler Thomson, built a combinatorial library of 384 ionizable lipids and screened them against a 5.7-kilobase reporter mRNA encoding an adenine base editor fused to NanoLuc, a luminescent protein. Crucially, the screen was conducted with the large cargo in hand, so the selection pressure reflected the real-world payload rather than a convenient stand-in. The top performer from that screen, LC-1, outshone both LP-01 and ALC-0315 when the same formulations were challenged with large mRNAs, and the advantage held across multiple cell types in culture.

The in vivo results are the heart of the study. When LC-1 nanoparticles carrying Cas9 mRNA and guide RNAs were injected intravenously into Ai9 reporter mice, which light up fluorescently when Cre-mediated recombination occurs, the team measured knockout of the reporter gene in up to 79 percent of liver cells. More remarkable still, LC-1 achieved 48 percent editing in the brain and 27 percent in the lung, depending on the route of administration, which included intrathecal injection into the spinal fluid and intratracheal delivery to the airways. Those figures represent up to fourfold improvements over the benchmark lipids LP-01 and ALC-0315 under the same conditions. For a field in which extrahepatic delivery has long been the bottleneck, editing nearly half of the relevant cells in brain tissue is a striking result.

The researchers then pushed the platform toward therapeutic targets. LC-1 supported base editing of PCSK9 in the liver, a gene whose disruption durably lowers LDL cholesterol and has already been validated in nonhuman primates as a potential one-time treatment for cardiovascular disease. In the lung, the team edited CFTR carrying the R55X mutation, a nonsense variant relevant to cystic fibrosis, where even partial restoration of functional protein is expected to ameliorate disease severity. And in the brain, delivered via intrathecal injection, LC-1 enabled editing at the Ube3a-ATS locus, the long noncoding RNA that silences the paternal copy of Ube3a in neurons. Reactivating that paternal allele is a leading strategy for treating Angelman syndrome, a severe neurodevelopmental disorder. Across all three routes of administration, LC-1 also produced higher correction rates in the LumA reporter mouse model of adenine base editing than the comparison lipids.

Why does LC-1 succeed where established lipids falter? The mechanistic studies in the paper offer an answer grounded in lipid physical chemistry. Using structural analyses, the team found that LC-1 forms stronger interactions with RNA and, critically, retains an ordered, fusogenic inverted-hexagonal phase as mRNA size increases. The inverted hexagonal phase is a nonbilayer lipid arrangement long associated with membrane fusion: lipids in this geometry promote contact between the nanoparticle and the endosomal membrane, allowing the RNA to escape into the cytoplasm rather than being routed to the lysosome for degradation. LC-1 also preserves pH-responsive membrane disruption as the cargo grows. The benchmark lipids, by contrast, become structurally disordered when loaded with large transcripts, losing the very geometry that enables endosomal escape. In other words, big RNA destabilizes ordinary particles but leaves LC-1’s fusogenic architecture intact.

The authors traced these properties to specific subchemical features of the lipid structure, showing how variations in the lipid’s building blocks influence both endosomal escape and the internal organization of the particle. That structure-function insight is arguably the study’s most consequential contribution, because it converts cargo size from an afterthought into a rational design variable. Screening libraries against a representative large transcript, the work suggests, should become standard practice for anyone developing ionizable lipids intended for genome editing, self-amplifying RNA, or other oversized payloads. It also complements a growing toolkit of approaches for tissue targeting, from selective organ targeting formulations to ligand-decorated particles, by ensuring that once a particle reaches its destination cell, it can actually deliver the goods.

Caveats remain before such particles reach the clinic. The results are in mice, and serum factors are known to create species-specific barriers to lipid nanoparticle delivery, meaning performance in larger animals and humans must be demonstrated. Dosing, biodistribution, immune responses to repeated administration, and long-term safety all require further study. The inventors have filed an invention disclosure through the University of Toronto, and the corresponding author serves as an advisor to biotechnology companies, so commercial development is likely to follow. Still, the demonstration that a single optimized lipid can mediate efficient editing in liver, brain and lung through intravenous, intrathecal and intratracheal routes marks a meaningful advance. If the large-cargo-informed design principle generalizes, it could widen the path toward nonviral, potentially redosable gene-editing medicines for diseases of the heart, the airway and the nervous system.

Subject of Research: Design of large-cargo-optimized ionizable lipids for lipid nanoparticle delivery of genome-editing RNA in vivo

Article Title: Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing

Article References: Dong, S., Gong, F., Thomson, T., Cai, Y., Healy, L., Lu, R. X. Z., Zhou, Z., Xu, Y., Chen, J., Savguira, M., Fu, X., Luozhong, S., Zhou, M., Kirtley, P., Wilder, B. K., & Li, B. (2026). Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03298-8

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03298-8

Keywords: lipid nanoparticles, ionizable lipids, genome editing, CRISPR, Cas9, base editing, mRNA delivery, endosomal escape, PCSK9, CFTR, Angelman syndrome, drug delivery

The core problem the authors confront is one of specificity. CRISPR-Cas9 can, in principle, rewrite the genome with nucleotide-level precision, disabling oncogenic drivers, restoring tumor suppressor pathways, or reprogramming regulatory noncoding elements. In practice, however, the Cas9 protein and its guide RNA are large, charged biological molecules that do not cross cell membranes on their own, degrade rapidly in the bloodstream, and can trigger off-target edits when they reach the wrong cells. Current viral vectors such as adeno-associated virus, or AAV, offer efficient delivery but raise concerns about insertional mutagenesis, limited cargo capacity, immunogenicity, and the sheer difficulty of restricting their tropism to cancer cells alone. Nonviral alternatives have historically suffered from low efficiency. The review positions aptamer-mediated delivery as a way out of this impasse.

Aptamers are selected through an iterative laboratory process known as SELEX, systematic evolution of ligands by exponential enrichment, which screens enormous random-sequence libraries for strands that bind a chosen target with high affinity. Unlike antibodies, aptamers are chemically synthesized, minimally immunogenic, small enough to penetrate dense tumor tissue, and can be modified at will with fluorescent tags, linker chemistries, or therapeutic payloads. The review catalogs aptamers directed against a who’s-who of tumor-associated surface markers: epithelial cell adhesion molecule (EpCAM) overexpressed on many carcinomas, epidermal growth factor receptor (EGFR) in lung and colon cancers, human epidermal growth factor receptor 2 (HER2) in breast cancer, prostate-specific membrane antigen (PSMA) in prostate cancer, nucleolin and protein tyrosine kinase 7 (PTK7) on a range of malignant cells, and the transferrin receptor, which is abundant on the blood-brain barrier and on glioblastoma cells. Each of these ligands can, in principle, be conjugated to a nanocarrier carrying Cas9 ribonucleoprotein complexes or plasmid DNA, converting a systemically administered particle into a homing missile for tumor cells.

One of the most technically interesting contributions of the review is its emphasis on structure-guided molecular docking as a design tool. Rather than relying purely on trial and error, the authors describe how computational docking and molecular dynamics simulations can predict the binding energetics of an aptamer-receptor pair before any wet-lab work begins. By modeling the three-dimensional folds that aptamers adopt, researchers can rationally introduce mutations that strengthen the binding interface, improve discrimination between the tumor target and closely related proteins on healthy cells, and truncate aptamers to the minimal binding domain, reducing manufacturing cost and immunogenic potential. This computational-first workflow, the review argues, is transforming aptamer engineering from an artisanal craft into a predictable engineering discipline.

Getting the particle bound to the cell surface, however, is only the first hurdle. The review devotes substantial attention to what happens next: receptor-mediated endocytosis, the process by which the cell swallows the bound particle into an endosome, followed by the equally critical step of endosomal escape. Most nanoparticles that successfully enter cells end up trapped and degraded in lysosomes, which is why delivery efficiency is often measured in frustratingly low single digits. The authors survey the escape strategies now being built into aptamer-functionalized carriers, including proton-sponge effects from polyethylenimine-based formulations, pH-responsive membrane-disruptive polymers, and fusogenic lipids that destabilize the endosomal membrane as its interior acidifies. Understanding which endocytic pathway, clathrin-mediated, caveolae-mediated, or macropinocytosis, a given aptamer-receptor pair exploits allows researchers to co-opt the cell’s own trafficking machinery and steer the cargo toward the cytosol and ultimately the nucleus, where Cas9 must arrive to do its work.

The third pillar of the framework is nanocarrier engineering, and here the review offers a sweeping comparison of the leading platforms. Lipid nanoparticles, validated clinically by the mRNA vaccine campaigns, remain the front-runner, with refinements in PEG-lipid architectures, such as cleavable DSPE-PEG anchors and optimized PEG densities, improving colloidal stability while avoiding accelerated blood clearance on repeat dosing. Polymeric carriers built from PLGA and PAMAM dendrimers offer controlled release profiles, while inorganic platforms, including mesoporous silica nanoparticles and gold nanoparticles, provide stimulus-responsive gates that open in the acidic tumor microenvironment. Extracellular vesicles, the natural nanoshuttles secreted by cells themselves, offer innate biocompatibility and the ability to cross biological barriers, and hybrid viral-nonviral platforms attempt to marry viral entry efficiency with the safety and tunability of synthetic materials.

What distinguishes this review from earlier surveys of CRISPR delivery is its insistence that these three elements, targeting ligand, trafficking route, and carrier chemistry, must be co-optimized rather than designed in isolation. A particle decorated with a superb aptamer but lacking endosomal escape capability will never deliver an active nuclease. A carrier with perfect intracellular performance but rapid serum clearance will never reach the tumor. The authors highlight how the dense, fibrotic extracellular matrix of many tumors physically blocks nanoparticle penetration, and how aptamer-mediated binding to receptors expressed deep within tumor spheroids can enhance accumulation in poorly perfused regions. They also discuss spatiotemporally controlled editing, in which carriers release their cargo only in response to tumor-specific cues such as hypoxia, low pH, or externally applied light or ultrasound, limiting genome modification to the tumor microenvironment.

The potential clinical applications span the full breadth of oncology. Targeted knockout of oncogenic drivers such as mutant EGFR in non-small cell lung cancer, disruption of the Wnt pathway via adenomatous polyposis coli-related targets in colorectal cancer, editing of immune checkpoints such as PD-1 to unleash antitumor immunity, and correction of tumor suppressor defects through homology-directed repair are all within the conceptual scope of aptamer-guided delivery. The authors also note synergies with established modalities: aptamer-targeted carriers could deliver Cas9 engineered to knock out drug-resistance genes alongside conventional chemotherapy, or complement CAR T-cell therapy by editing immune cells ex vivo with higher efficiency and lower toxicity than viral transduction.

The authors are admirably candid about the obstacles that remain. In vivo stability of both aptamers and Cas9 cargos in the face of nucleases and proteases, the scalability and reproducibility of GMP-grade nanomanufacturing, the persistent specter of off-target double-strand breaks, and the dearth of rigorous long-term preclinical and clinical validation all stand between the current state of the art and routine bedside use. Aptamer affinity measured in a culture dish does not always translate to four-hour circulation in human plasma, and off-target editing in non-tumor tissue remains the field’s most serious safety concern. Yet the trajectory is unmistakable. By integrating rational aptamer design, mechanistic understanding of intracellular trafficking, and increasingly sophisticated nanocarrier engineering, the field is assembling the complete delivery toolkit that precision genome editing oncology has been waiting for. If the remaining challenges can be met, aptamer-guided CRISPR-Cas9 systems could move genome surgery from the laboratory bench to the cancer clinic, offering patients therapies that edit the disease at its genetic source while sparing healthy tissue entirely.

Subject of Research: Aptamer-mediated CRISPR-Cas9 delivery systems for targeted cancer genome editing

Article Title: Aptamer-mediated CRISPR-Cas9 delivery for precision oncology: integrating molecular targeting, intracellular trafficking, and nanocarrier engineering

Article References: Saffari Natanzi, A., Ahmadi, E., Shahraki, S., Eslamian Koupaei, A., & Haddad Kashani, H. (2026). Aptamer-mediated CRISPR-Cas9 delivery for precision oncology: integrating molecular targeting, intracellular trafficking, and nanocarrier engineering. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02049-2

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02049-2

Keywords: aptamers, CRISPR-Cas9, precision oncology, targeted delivery, nanocarriers, lipid nanoparticles, gene editing, endosomal escape, molecular docking, SELEX, tumor microenvironment, cancer therapy

To appreciate why this charge choreography matters, it helps to revisit how standard lipid nanoparticles work. A typical formulation combines an ionizable lipid with helper lipids, cholesterol, and polyethylene glycol-conjugated lipids, all assembled around a nucleic acid payload such as mRNA or siRNA. The ionizable lipid is engineered with an amine group whose protonation state depends on acidity: at the near-neutral pH of blood, roughly 7.4, the lipid is mostly uncharged, which keeps the particle circulations friendly and limits interactions with serum proteins and cell membranes. When the particle is taken up by a cell and lands in an endosome, whose interior becomes progressively more acidic, the amine group acquires a positive charge. This electrostatic switch lets the lipid blend with and destabilize the endosomal membrane, allowing the payload to escape into the cytoplasm where it can be translated or processed.

The problem is that cationic charge is inherently disruptive. Positively charged lipids and particles can bind avidly to negatively charged cell surfaces, destabilize plasma membranes, and trigger innate immune signaling pathways, including inflammasome activation and inflammatory cytokine release. Clinicians see the consequences as infusion reactions, fever, and dose-limiting toxicities that constrain how much therapeutic material can be administered, a particular obstacle for applications that require repeated or systemic dosing. Preclinical studies have long documented that ionizable lipids with lower pKa values and more biodegradable linkages tend to be better tolerated, but the field has continued to search for designs that decouple endosomal escape efficiency from extracellular reactivity.

The S-lipids described in the new work take that decoupling a step further. Instead of merely being less protonated at physiological pH, these lipids are designed to carry a neutral or even negative charge while circulating, so that the nanoparticle surface presents little of the cationic character associated with membrane damage and immune activation. Only when the particle encounters the strongly acidic environment inside endosomes does the chemical group undergo its switch, becoming positively charged at precisely the moment and location where membrane disruption is useful. In effect, the designers have shifted the charge transition from a gradual acid-base titration to a sharper, compartment-specific event, concentrating cationic activity where it helps and eliminating it where it harms.

According to the study, lipid nanoparticles built from these charge-switching lipids deliver nucleic acids with an efficiency comparable to that of conventional ionizable lipid formulations, despite presenting a non-cationic exterior in the extracellular environment. In cell-based assays and animal models, the S-lipid nanoparticles induced substantially reduced inflammatory responses, a difference the authors attribute to the absence of persistent positive surface charge during circulation and initial cell contact. The findings suggest that the inflammation commonly associated with lipid nanoparticle therapy is driven in large part by cationic interactions that occur before the particle ever reaches an endosome, and that these interactions can be engineered away without sacrificing the delivery mechanism that makes the technology valuable.

The implications reach across the growing portfolio of nucleic acid medicine. mRNA vaccines and therapeutics, siRNA gene silencing, CRISPR-based genome editing, and prime editing strategies all depend on lipid nanoparticles or close cousins to ferry their fragile cargo past cell membranes and endosomal traps. Each of these modalities is limited by the maximum tolerated dose of lipid. If charge-switching lipids genuinely lower toxicity while preserving potency, they could raise the ceiling on how much genetic instruction or editing machinery can be delivered in a single treatment, which in turn could improve efficacy against tumors, extend duration of protein expression, or reduce the frequency of dosing for chronic conditions. Safer lipids would also matter for patients with pre-existing inflammatory conditions, for whom even mild cytokine activation can be clinically significant.

The chemistry behind the switch reflects a broader trend in nanomedicine toward stimuli-responsive materials. Researchers have previously explored pH-sensitive polymers, acid-labile linkers, and ionizable heads with tuned pKa values, all in pursuit of the same goal: keeping a delivery vehicle inert in circulation and active inside the cell. The S-lipid approach refines this strategy at the level of the lipid headgroup itself, encoding environmental sensitivity into the molecular structure rather than relying on a detachable protecting group or a formulation additive. Such intrinsic responsiveness can be advantageous because it does not depend on a chemical reaction that competes with biological degradation, and because the behavior of the particle is determined uniformly by every lipid molecule in its shell.

There are, of course, familiar gaps between promising preclinical materials and routine clinical tools. Charge-switching lipids must demonstrate manufacturability at scale, stability during storage, predictable behavior across species, and safety profiles that satisfy regulators over repeated exposures. The acidic microenvironments of tumors and inflamed tissues, which some delivery strategies exploit, could in principle trigger premature charge switching, although the authors’ data focus on the endosomal route that dominates lipid nanoparticle uptake. Biodistribution, complement activation, and long-term accumulation of the new lipid species in liver and other organs will require the same scrutiny applied to every prior generation of ionizable lipids. Still, the conceptual advance, that toxicity can be reduced by sharpening the pH dependence of lipid charge rather than by broadly softening the lipid, gives formulation scientists a new design axis to explore alongside biodegradability, pKa tuning, and structural diversity generated by combinatorial synthesis.

The study lands at a moment when the lipid nanoparticle pipeline is expanding far beyond its vaccine origins. Companies and academic groups are advancing inhaled, implantable, and targeted formulations; conjugating antibodies and ligands to particle surfaces; and exploring delivery to cell types, such as T cells and hematopoietic stem cells, that have resisted lipid-based transfection. Every one of those programs inherits the same core constraint of the cationic switch, and any chemistry that relaxes that constraint without weakening delivery is likely to be adopted quickly. As the field matures from proving that nucleic acid delivery works to optimizing how well and how safely it works, charge-switching S-lipids offer a concrete, mechanistically grounded answer to one of the platform’s oldest criticisms: that the vehicle that saves the payload from destruction should not itself become the source of the patient’s discomfort.

For now, the result stands as an elegant demonstration that a single, well-chosen molecular property, the timing of a charge transition, can reshape the biological personality of an entire delivery platform. If subsequent studies in larger animals and human trials confirm the reduced inflammation reported here, the modest S-lipid may take its place alongside the ionizable lipids that preceded it as a quiet but consequential upgrade to the technology that carried mRNA medicine into the clinic.

The distinction between a gradual titration curve and a sharp switching threshold has practical consequences for how such particles behave in blood. Serum albumin and other abundant proteins carry their own net charges, and conventional ionizable lipid nanoparticles can acquire a protein corona whose composition influences both clearance and immune recognition. A particle surface that presents neutral or anionic character should interact with this corona differently, potentially altering which proteins adsorb and how the particle is routed through the liver and spleen. The authors’ observation that reduced inflammation tracks with the absence of persistent cationic surface charge is consistent with this picture, though the precise corona composition of S-lipid formulations remains an open question for follow-up work.

Endosomal escape itself remains one of the least efficient steps in the delivery process, with estimates suggesting that only a small fraction of internalized nucleic acid ever reaches the cytoplasm. Any headgroup chemistry that preserves membrane-disruptive activity at endosomal pH while silencing it elsewhere therefore addresses the central bottleneck rather than trading one limitation for another. The sharper pH dependence reported for S-lipids suggests that the protonation event can be concentrated within the narrow acidity range of late endosomes, where the payload must be released, rather than beginning in early endosomes or, worse, at the cell surface.

It is also worth noting that inflammation from lipid nanoparticles is not a single mechanism but a collection of overlapping pathways, including complement activation, toll-like receptor signaling, and inflammasome engagement, each with different dose thresholds and kinetics. Reducing cationic contact may dampen several of these at once, but disentangling which pathways are most sensitive to surface charge will help predict which patient populations benefit most. Such mechanistic mapping, together with head-to-head comparisons against clinically validated ionizable lipids, will determine whether the safety margin demonstrated in preclinical models translates into meaningfully higher tolerated doses in humans.

Subject of Research: Development of charge-switching ionizable lipids that reduce the toxicity and inflammatory effects of lipid nanoparticles for nucleic acid delivery.

Article Title: Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles

Article References: Liang, D., Qi, Y., Han, H., Ahmadian, N., Gao, K., Sapasap, K., Zhang, Y., Guo, S., Lawanprasert, A., Pimcharoen, S., Zhao, S., Del Buono, M. T., Xia, H., Enders, Z. O., Burgstone, B. W., Calio, A., Dankar, N., Lu, B., Qi, L. S., … Murthy, N. (2026). Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles. Nature Nanotechnology. https://doi.org/10.1038/s41565-026-02262-6

Image Credits: AI Generated

DOI: 10.1038/s41565-026-02262-6

Keywords: lipid nanoparticles, ionizable lipids, charge-switching, mRNA delivery, nucleic acid delivery, inflammation, nanotechnology, endosomal escape, drug delivery, RNA therapeutics, biocompatibility, nanomedicine